PT  - JOURNAL ARTICLE
AU  - Patel, Abhilasha P.
AU  - Welling, Arpita A.
AU  - Vaidya, Vinay G.
AU  - Kulkarni, Padmaj S.
TI  - Simulation of COVID-19 Incubation Period and the Effect of Probability Distribution Function on Model Training Using MIMANSA
AID  - 10.1101/2020.06.18.20134460
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.18.20134460
4099  - http://medrxiv.org/content/early/2020/06/20/2020.06.18.20134460.short
4100  - http://medrxiv.org/content/early/2020/06/20/2020.06.18.20134460.full
AB  - Coronavirus disease 2019 (COVID-19) has infected people all over the world. While scientists are busy finding a vaccine and medicine, it becomes difficult to control the spread and manage patients. Mathematical models help one get a better feel for the challenges in patient management. With this in mind, our team developed a model called Multilevel Integrated Model with a Novel Systems Approach (MIMANSA) Welling et. al (2020). MIMANSA is a multi-parametric model. One of the challenges in the design of MIMANSA was to simulate the incubation period of coronavirus. The incubation period decides when virus-infected patients would show symptoms. The probability distribution function (PDF), when applied to the number of virus-infected cases, gives a good representation of the process of the incubation period. The probability distribution functions can take various forms. In this paper, we explore a variety of PDFs and their impact on parameter estimation in the MIMANSA model. For our experiments, we used Weibull, Gaussian, uniform, and Gamma distribution. To ensure a fair comparison of Weibull, Gaussian, and Gamma distribution, we matched the peak value of the distribution. Our results show that the Weibull distribution with shape 7.7 and scale 7 for 14 days gives a better training model and predictions.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNoneFunding StatementPi Innovate, Pune, IndiaAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not requiredAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yescovid19india.org https://www.COVID19india.org/